Added to YB: 2025-10-14
Pitch date: 2025-10-10
NVO [neutral]
Novo Nordisk A/S
-16.98%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.4T
Pitch Price
DKK 370.25
Price Target
N/A
Dividend
3.76%
EV/EBITDA
9.60
P/E
13.52
EV/Sales
4.81
Sector
Pharmaceuticals
Category
value
Show full summary:
Theodosian Capital | NOVOB – $5bn acquisition
NVO (update): $5.2bn Akero acquisition adds best-in-class MASH asset, strategic fit with 40% MASH patients having T2D, 80%+ overweight. Deal costs 3% FY26 op profit growth from higher R&D but zero rev until 2028+. Trades 14.4x 2026 PE, 3.5% yield, modest vs $262bn market cap.
Read full article (1 min)